Direct-acting antivirals
55 articles
Gilead’s HCV Drug Sofosbuvir Approved by the FDA but Accessible for How Many?
Press Release – 9 December 2013 / Bangkok – Paris – Basel – London – New York
On 6 Dec 2013, FDA approved Gilead’s HCV drug Sovaldi. Yet its anticipated price tag of $80,000 will ensure this drug remains out of reach for the vast majority of people with HCV. More
Pharma Refuses to Ensure Access to Lifesaving Hepatitis C Treatment at Global Meeting
Bangkok, Thailand, 28 February 2014
Activists from 22 countries joined forces at the first-ever HCV World CAB to demand equitable access to HCV treatment from six multinational pharmaceutical companies. More
New Treatments for Hepatitis C Virus: Strategies for Achieving Universal Access
“There is no question that these treatments that can save millions of lives must be made universally available at an affordable price.” More
Defuse Hepatitis C, the Viral Time Bomb: Test and Treat Hepatitis C
Position paper for the 67th World Health Assembly, 19–24 May 2014
People living with HCV, HIV/AIDS, people who use drugs, and their advocates, urge United Nations Member States to act with urgency to end the hepatitis C epidemic; it is possible! More
Today New Hepatitis Resolution is Passed at World Health Assembly; Challenges WHO and Member States to Act
Press Release – 22 May 2014 – Geneva
The World Health Assembly passed new Hepatitis Resolution committing WHO and UN member states to urgent action to address the global hepatitis pandemic. More
